Product Images Clopidogrel

This is a description for a medication packaging for Clopidogrel tablets. The tablets come in a bottle that should be stored at 20-25°C and protected from moisture. Each tablet contains 97,875 mg of Clopidogrel Bisulfate, which is equivalent to 75 mg of Clopidogrel base. The package includes a package insert binder for dosage information. The manufacturer is Apotex and it is packaged by Vangard. The lot number is included in the package and the overall configuration of the package is a trademark of Omnicare, Inc.*

This is a label of Clopidogrel Tablets USP, 75 mg, manufactured by Apotex. Each tablet contains 57,875 mg of clopidogrel bisulfite/78 mg of clopidogrel base. It is for institutional use only and must be stored at 20°- 25°C (68% - 77°F), protected from moisture.*

This is a figure showing the effect of different proton pump inhibitors (PPIs) on the exposure of active metabolite of Clopidogrel following multiple doses of Clopidogrel 75 mg alone or with PPIs. The figure presents mean and 90% confidence interval of the effect of different PPIs including Dextansoprazole, Lansoprazole, Pastoprazole, and Omeprazole on the active metabolite AUC. The X-axis represents the timepoints while the Y-axis represents the change relative to Clopidogrel administered alone.*

The figure shows the cumulative event rate of cardiovascular death, myocardial infarction, and stroke in the CURE study. The event rate is expressed in percentage and is compared between placebo (with aspirin) and clopidogrel (with aspirin) treatments. Other standard therapies were also used. The study followed up for several months, as indicated in the X-axis. The difference in event rate between the two treatments was statistically significant (P=0.00009).*

Figure3: Hazard Ratio is a statistical term used to measure the likelihood of an event occurring in one group compared to the probability of it occurring in another group. The table presented here provides data from the CURE study on various patient baseline characteristics and on-study concomitant medications or interventions. However, due to errors, the text could not be completely readable.*

The text contains the description of Figure 4 which shows cumulative event rates for death in the COMMIT Study. The figures display the percentages of deaths before and after a proportional reduction, with a P-033 value of 7%. There is an additional note indicating that all included patients received treatment, but the rest of the data is not available.*

This is a figure from the COMMIT study demonstrating the cumulative event rates for the combined endpoint of re-infarction, stroke, or death. The study included a placebo group with 10.1% of participants experiencing the combined endpoint and a group treated with clopidogrel with 8.2% experiencing the combined endpoint, resulting in a proportional risk reduction of 9%. The endpoints were assessed up to 28 days after randomization, and all participants received aspirin.*

This is a report on the effects of adding clopidogrel to aspirin on the combined primary endpoint across different concomitant medication subgroups for a study called COMMIT. There is also information regarding baseline counts, categories, and some values. The report mentions three prognostic index groups that were based on absolute risk of primary composite outcome for each patient that were calculated from baseline prognostic variables using a Cox regression model.*

The text provides a figure (Figure 8) with a graph showing the cumulative rate of fatal or non-fatal vascular events during the course of the CAPRIE study. The study involved the use of clopidogrel, a medication used to prevent blood clots, and followed patients for up to 80 months.*